U.K. likely to pay for Avastin despite another NICE rejection
Cancer drug most prescribed under separate government cancer fund.04/20/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 20, 2013 Category: Cancer & Oncology Source Type: news

Bevacizumab No Extra Help in Metastatic Breast CancerBevacizumab No Extra Help in Metastatic Breast Cancer
In metastatic breast cancer, adding bevacizumab to first-line chemotherapy improves progression-free survival (PFS) when tumors are HER2-negative - but not, as researchers just found out, when they're HER2-positive. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2013 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Ranibizumab or Bevacizumab in Patients With Neovascular AMDRanibizumab or Bevacizumab in Patients With Neovascular AMD
Is there a particular anti-VEGF agent that works best in neovascular AMD? This new study compares ranibizumab and bevacizumab. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Negative NICE Decision For Avastin® (Bevacizumab) Highlights Challenges Facing UK Access To Medicines
Roche is disappointed that the National Institute for Health and Clinical Excellence (NICE) has published a negative final recommendation (FAD) for the use of Avastin (bevacizumab) in combination with paclitaxel and carboplatin for women with newly-diagnosed advanced ovarian cancer*.(1) This negative decision means that women will continue to rely on their clinicians' successful application to the Cancer Drug Fund (CDF) to access this treatment for advanced ovarian cancer in England... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 26, 2013 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

FDA alerts health care providers and patients of the nationwide recall of all lots of sterile products distributed by Clinical Specialties Compounding Pharmacy
The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary recall of all lots of sterile products produced and distributed by Clinical Specialties Compounding Pharmacy (CSCP) of Augusta, Ga. The recall of all sterile products is due to the FDA’s preliminary findings of practices at the site which raise concerns about a lack of sterility assurance. This expanded recall is due to reports of five patients who have been diagnosed with serious eye infections associated with use of Avastin (bevacizumab) repackaged into syringes by CSCP. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 21, 2013 Category: American Health Source Type: news

Compounder Recalls Avastin Syringes, Other Products
(MedPage Today) -- A Georgia compounding pharmacy has recalled all of its sterile products, expanding the recall of its bevacizumab (Avastin) syringes announced yesterday, according to the FDA. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - March 21, 2013 Category: Opthalmology Source Type: news

Clinical Specialties Compounding Pharmacy Products: Recall - All Sterile Products Recalled Due To Lack of Sterility Assurance
Expanded recall follows the firm’s initial recall of Avastin. (Source: FDA MedWatch)
Source: FDA MedWatch - March 21, 2013 Category: American Health Source Type: news

FDA Warns of Eye Infections From Unapproved Avastin
Federal regulators are warning about eye infections linked to a recall of unapproved Avastin syringes made by a Georgia compounding pharmacy. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 21, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Georgia compounding pharmacy recalls Avastin after reports of eye infections
Compounding pharmacies repackage cancer drug Avastin for eye doctors because it contains same ingredient as macular degeneration drugs (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 20, 2013 Category: Consumer Health News Source Type: news

Avastin Unit Dose Syringes by Clinical Specialties: Recall - Potential For Serious Eye Infection
Clinical Specialties received reports of five intra-ocular infections from physician’s office. (Source: FDA MedWatch)
Source: FDA MedWatch - March 20, 2013 Category: American Health Source Type: news

Compounding Pharmacy Crackdown Continues With Avastin RecallCompounding Pharmacy Crackdown Continues With Avastin Recall
The drug, used on an off-label basis to treat macular degeneration, has cropped up before in contamination cases that have left patients blind. News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 19, 2013 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

News from the SGO Annual Meeting
Highlights from research presented at the March 2013 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.From March 9-12, 2013 top women’s cancer doctors from all over the world met in Los Angeles for the Society of Gynecologic Oncology's Annual Meeting on Women’s Cancer.  Lots of exciting research was presented at the meeting, representing the latest in the care and treatment of women with ovarian and other gynecologic cancers.  Highlights from research presented at the meeting include:     • Patients with advanced ovarian cancer who underwent intraperiton...
Source: OCRF News - March 15, 2013 Category: Cancer & Oncology Source Type: news

Pharmaceutical companies fund Interpol fight against fake prescription drugs
Three times last year U.S. health officials warned about counterfeit versions of the cancer drug, Avastin (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 12, 2013 Category: Consumer Health News Source Type: news

NCI Grantees Receive Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences recognizes “excellence in research aimed at curing intractable diseases and extending human life.” The inaugural set of prizes, awarded in February 2013 by a not-for-profit corporation dedicated to advancing breakthrough research, are backed by well-known personalities such as Sergey Brin, Google co-founder and his wife, Anne Wojcicki, co-founder of a personal genomics and biotech company 23andMe; Facebook founder Mark Zuckerberg  and his wife, Priscilla Chan; Russian entrepreneur Yuri Milner; and  Art Levinson, chairman of Apple and Genentech. The 11 recip...
Source: NCI Benchmarks - March 8, 2013 Category: Cancer & Oncology Authors: Aleea Farrakh Khan Tags: Scientist Spotlight award Source Type: news

Q&A: Valerie Harper’s Cancer
WebMD Medical News By Kathleen Doheny Reviewed by Brunilda Nazario, MD March 6, 2013 — Actress Valerie Harper, best known for her role as Rhoda Morgenstern on The Mary Tyler Moore Show  and Rhoda in the 1970s, has learned she has leptomeningeal carcinomatosis. The condition happens when cancer spreads to the brain and spinal cord. Now 73, Harper told People magazine she received the diagnosis in January. The American Cancer Society has no specific statistics on this complication. Some research estimates it happens in about 5% to 10% of patients with cancer. WebMD asked Henry S. Friedman, MD, deputy directo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 7, 2013 Category: Consumer Health News Authors: mreal197 Tags: WebMD News Source Type: news

FOLFOXIRI Bests FOLFIRI When Bevacizumab is Added in Colorectal Cancer
SAN FRANCISCO (IMNG) - Adding bevacizumab to the FOLFOXIRI regimen significantly delayed the median time to progression of metastatic colorectal cancer to 12.2 months, compared with 9.7 months when bevacizumab... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 27, 2013 Category: Cancer & Oncology Source Type: news

Combo Tx No Better for Renal Cancer
ORLANDO (MedPage Today) -- Combination therapy for metastatic renal cell carcinoma failed to improve outcomes compared with bevacizumab alone and caused more toxicity, results of a randomized trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - February 18, 2013 Category: Journals (General) Source Type: news

Bevacizumab And Dasatinib Combination Shows Promise In Fighting Glioblastoma
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens. They have also discovered that pairing Avastin with another cancer drug, dasatinib, can stop that lethal spread. Dasatinib is approved for use in several blood cancers. The findings, based on an animal study, are detailed in the online issue of PLOS ONE... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 18, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Combo of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds
Mayo Clinic researchers have discovered that pairing Avastin with another cancer drug, dasatinib, can help stop an aggressive brain cancer from spreading from spreading throughout the brain. (Source: Mayo Clinic Jacksonville News)
Source: Mayo Clinic Jacksonville News - February 15, 2013 Category: Hospital Management Authors: Mayo Clinic Source Type: news

Combo of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds
Mayo Clinic researchers have discovered that pairing Avastin with another cancer drug, dasatinib, can help stop an aggressive brain cancer from spreading from spreading throughout the brain. (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 15, 2013 Category: Databases & Libraries Authors: Mayo Clinic Source Type: news

Combo of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds
Mayo Clinic researchers have discovered that pairing Avastin with another cancer drug, dasatinib, can help stop an aggressive brain cancer from spreading from spreading throughout the brain. (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - February 15, 2013 Category: Research Authors: Mayo Clinic Source Type: news

LCNDG Rapid Review: Axitinib as an option for second line advanced renal
Source: London Cancer New Drugs Group Area: Evidence> Drug Specific Reviews Axitinib (Inlyta®, Pfizer) is an orally administered multi-targeted kinase receptor inhibitor that has been licensed in the EU for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. There are currently no treatments approved by NICE for use in people with advanced RCC who have failed to respond to prior systemic therapy. However, sunitinib and everolimus are occasionally prescribed as second-line treatments through the Cancer Drugs Fund; and are also sugges...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news

Combo Of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds
The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 15, 2013 Category: Pharmaceuticals Source Type: news

Combo of Avastin, second drug shows promise fighting brain cancer, Mayo Clinic finds
(Mayo Clinic) The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2013 Category: Cancer & Oncology Source Type: news

Institute of Medicine calls for better tracking system to fight counterfeit drug trade
Report follows third warning in a year of fake batches of the cancer drug, Avastin (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 13, 2013 Category: Consumer Health News Source Type: news

Institute of Medicine Seeks to Combat Conterfeit Drug Problem
Fighting the problem of fake drugs will require putting medications through a chain of custody like U.S. courts require for evidence in a trial, the Institute of Medicine reported Wednesday.The call for a national drug tracking system comes a week after the Food and Drug Administration warned doctors, for the third time in about a year, that it discovered a counterfeit batch of the cancer drug Avastin that lacked the real tumor-killing ingredient. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 13, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

Bevacizumab Plus Chemo Extends Survival in Metastatic Cervical Cancer
Adding bevacizumab to chemotherapy extended survival by about 4 months beyond the survival achieved with chemotherapy alone in chemotherapy-naïve patients with persistent, recurrent, or metastatic cervical... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 12, 2013 Category: Cancer & Oncology Source Type: news

FDA detects a new counterfeit bevacizumab
Read the full story on MD Consult: FDA detects a new counterfeit bevacizumab (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - February 12, 2013 Category: Journals (General) Source Type: news

Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Title: Avastin May Help Boost Survival With Aggressive Cervical Cancer: StudyCategory: Health NewsCreated: 2/8/2013 2:36:00 PMLast Editorial Review: 2/11/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 11, 2013 Category: Cancer & Oncology Source Type: news

Horizon scanning: Interim analysis shows improved survival with bevacizumab in recurrent and metastatic cervical cancer
Source: PharmaLive Area: News PharmaLive has reported on the results of an interim analysis of the GOG240 randomised controlled trial, which evaluated the addition of bevacizumab to chemotherapy in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment.   The study enrolled 452 patients in the US and Spain between 2009 and 2012, and was designed to address two questions: 1) is topotecan plus paclitaxel superior to cisplatin plus paclitaxel in combination and 2) does the addition of bevacizumab to either regimen improved overall survival (OS). Patients were th...
Source: NeLM - News - February 11, 2013 Category: Drugs & Pharmacology Source Type: news

Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Women taking the drug lived more than 3 months longer on average, but side effects were an issue (Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - February 9, 2013 Category: Cancer & Oncology Source Type: news

Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Women taking the drug lived more than 3 months longer on average, but side effects were an issue (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 8, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Avastin May Help Boost Survival with Aggressive Cervical Cancer
Women taking the drug lived more than 3 months longer on average, but side effects were an issue Source: HealthDay Related MedlinePlus Page: Cervical Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 8, 2013 Category: Consumer Health News Source Type: news

Bevacizumab Extends Survival in Advanced Cervical CancerBevacizumab Extends Survival in Advanced Cervical Cancer
This is a potentially practice-changing development, according to the National Cancer Institute. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Video: Online pharmacies: What you need to know
Another fake batch of the cancer drug Avastin turned up in the U.S., making it the third such case in the past year. Economist Roger Bate, the author of "Phake," speaks to the "CBS This Morning" co-hosts about the counterfeit drug problem online. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 8, 2013 Category: Consumer Health News Source Type: news

Avastin Boosts Survival in Cervical Cancer
(MedPage Today) -- Overall survival among patients with advanced cervical cancer was improved significantly with bevacizumab (Avastin), the National Cancer Institute announced. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 8, 2013 Category: Hematology Source Type: news

FDA Warns Again of Counterfeit Bevacizumab
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 8, 2013 Category: Primary Care Tags: Medical News Source Type: news

Avastin Found to Improve Survival in Cervical Cancer
Roche's cancer drug Avastin helped patients with advanced cervical cancer live longer, according to the interim results of a federally funded study. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 8, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer
Source: National Cancer Institute - Related MedlinePlus Page: Cervical Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 7, 2013 Category: Consumer Health News Source Type: news

FDA warns about fake Avastin again
The vials are packaged as Altuzan, the Turkish version of Avastin that is not approved for use in the U.S. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 7, 2013 Category: Consumer Health News Source Type: news

FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
Title: FDA Issues Another Warning on Fake Version of Cancer Drug AvastinCategory: Health NewsCreated: 2/6/2013 4:35:00 PMLast Editorial Review: 2/7/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 7, 2013 Category: Cancer & Oncology Source Type: news

Combination Therapy Better for Elderly With Colorectal Cancer
SAN FRANCISCO (IMNG) - Adding bevacizumab to capecitabine for first-line therapy for elderly patients with metastatic colorectal cancer significantly delayed disease progression and improved treatment... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 7, 2013 Category: Cancer & Oncology Source Type: news

FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
Patients who take the product would get no benefit, agency says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 7, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, Preventive Medicine, News, Source Type: news

FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
Patients who take the product would get no benefit, agency says (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - February 7, 2013 Category: Cancer & Oncology Source Type: news

OXiGENE completes toxicity analysis for Phase II ovarian cancer drug trial
OXiGENE has completed the toxicity analysis for its randomised Phase II trial of Zybrestat (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) in combination, indicated to treat patients with persistent or recurrent ovarian cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 7, 2013 Category: Pharmaceuticals Source Type: news

FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
Patients who take the product would get no benefit, agency says Source: HealthDay Related MedlinePlus Pages: Cancer Chemotherapy, Health Fraud (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 6, 2013 Category: Consumer Health News Source Type: news

FDA Warns of New Batch of Fake Cancer Drug
The FDA said Tuesday it has warned U.S. doctors that another batch of counterfeit Avastin, a cancer medicine, has reached American medical practices. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 6, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

23andMe: Innovation in Metastatic Cancer Researc
Genetics can sometimes explain why some people respond well to a drug whereas others may experience serious side effects. The InVite Study is a collaborative effort between 23andMe and Genentech to learn more about how genes influence response to bevacizumab (also known as Avastin®) in the treatment of locally recurrent or metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, or metastatic renal cell carcinoma.02/05/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 5, 2013 Category: Cancer & Oncology Source Type: news

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma
The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized.02/05/2013 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 5, 2013 Category: Cancer & Oncology Source Type: news

Taking a Break After 100 Cycles of BevacizumabTaking a Break After 100 Cycles of Bevacizumab
The last patient on the ECOG-2100 trial has stopped therapy after 100 cycles, and Dr. Kathy Miller reminds clinicians to treasure the exceptions for they can point the direction to new interventions. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news